
About Dinesh Mills
Dinesh Mills is a publicly listed company based in Vadodara (India) founded in 1935. Capsule manufacturing machines are produced by Dinesh Mills in India. The company has 322 employees. Its Indian entity Shri Dinesh Mills Limited reported revenue of βΉ79.95 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Similar companies include Akums, Jubilant Life Sciences and Nectar Lifesciences; 2 of its 3 listed similar companies have raised funding.
Company details
Dinesh Mills was established in 1935 in Vadodara, India, where operations center on the production of machinery for capsule manufacturing. The company serves the pharmaceutical equipment sector by providing machines used in capsule filling and production processes. Leadership is provided by Managing Director and Chairman Bharat Patel, with activities based primarily in the Indian market. Focus remains on industrial manufacturing standards and local operations.
- Headquarters Vadodara, India
- Employees 322
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website dineshmills.com
- Social LinkedIn
- Legal Name Shri Dinesh Mills Limited
- Date of Incorporation 01 Jul, 1935
- Jurisdiction Vadodara, Gujarat, India
- Market Cap₹211 Cr
SHRIDINE · BSE
- Share Price₹372.30
-1.05% today
- Revenue₹67.72 Cr
FY 2025-26 · +1.8% YoY
- EBITDA−₹0.26 Cr
Margin -0.4%
- Net Profit₹9.41 Cr
FY 2025-26 · +37.4% YoY
- P/E (TTM)15.3x
P/B 1.0x
- ROE4.7%
ROCE 5.7%
- Debt / Equity0.02
Interest cover -23.0x
- Employee Count322
Associated legal entities of Dinesh Mills
Dinesh Mills is associated with 2 registered companies on The Company Check; the primary company is Shri Dinesh Mills Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Shri Dinesh Mills Limited Listed CIN L13999GJ1935PLC000494 | Active | 01 Jul 1935 | Vadodara, Gujarat | ₹80.0 Cr | 322 | 10 | View details |
| Shri Dinesh Mills Limited CIN L17110GJ1935PLC000494 | 01 Jul 1935 | Vadodara, Gujarat, India | View details |
Board of directors of Shri Dinesh Mills Limited (Dinesh Mills)
Shri Dinesh Mills Limited is the primary company behind Dinesh Mills. The board of Shri Dinesh Mills Limited currently have 8 directors; the longest-serving is Nimish Patel, appointed in 1995. 16 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Nimish Patel DIN 00039549 | Managing Director | 14 Jan 1995 | 31 yrs 10 mo | Shri Dinesh Mills Limited |
| Bharat Upendra Patel DIN 00039543 | Managing Director | 01 Apr 2010 | 16 yrs 7 mo | Shri Dinesh Mills Limited |
| Reshma Suresh Patel DIN 00165162 | Director | 15 Mar 2021 | 5 yrs 8 mo | Shri Dinesh Mills Limited |
| Sameer Subhash Khera DIN 00009317 | Director | 23 May 2024 | 2 yrs 6 mo | Shri Dinesh Mills Limited |
| Shivindersingh Chawla DIN 02955805 | Director | 23 May 2024 | 2 yrs 6 mo | Shri Dinesh Mills Limited |
| Aditya Patel DIN 03292506 | Whole-time director | 23 May 2024 | 2 yrs 6 mo | Shri Dinesh Mills Limited |
| Nishank Patel DIN 05170801 | Whole-time director | 23 May 2024 | 2 yrs 6 mo | Shri Dinesh Mills Limited |
| Tejal Rahul Amin DIN 00169860 | Director | 28 Mar 2026 | 7 mo | Shri Dinesh Mills Limited |
People of Dinesh Mills
1 people are tracked at Dinesh Mills (1 in leadership); the tracked headcount is 322.
| Name | Role | Group |
|---|---|---|
| Managing Director & Chairman | Leadership |
Complete people profiles for Dinesh Mills
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Dinesh Mills
Dinesh Mills is a publicly listed company on the BSE with ticker symbol SHRIDINE in India, operating in the Textiles sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Sep 1970
- Listed onBSE: 503804
- Listed entityShri Dinesh Mills Limited
- Exchange sectorTextiles
Financials of Dinesh Mills
Exchange-reported figures of Shri Dinesh Mills Ltd, the listed company behind Dinesh Mills (BSE: SHRIDINE).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 67.72 | 66.53 | 67.12 | 98.17 | 90.16 | 74.16 | 66.16 |
| Revenue growth | +1.8% | -0.9% | -31.6% | +8.9% | +21.6% | +12.1% | - |
| EBITDA | (0.26) | 1.79 | 2.58 | 10.96 | 16.83 | 13.59 | 0.41 |
| EBITDA margin | -0.4% | +2.7% | +3.8% | +11.2% | +18.7% | +18.3% | +0.6% |
| Profit before tax | 8.43 | 11.85 | 60.24 | 29.07 | 36.59 | 11.68 | 0.14 |
| Net profit | 9.41 | 6.85 | 11.94 | 7.97 | 10.97 | 8.50 | (3.08) |
| Net profit margin | +13.9% | +10.3% | +17.8% | +8.1% | +12.2% | +11.5% | -4.7% |
| EPS (βΉ) | 13.57 | 18.73 | 90.25 | 42.38 | 53.61 | 17.53 | 2.07 |
| Balance sheet | |||||||
| Total assets | 208 | 211 | 243 | 193 | 163 | 129 | 115 |
| Net worth | 200 | 194 | 202 | 157 | 138 | 111 | 97.20 |
| Total debt | 2.38 | 4.77 | 23.80 | 13.63 | 7.09 | 5.34 | 5.55 |
| Cash & bank | 3.53 | 4.14 | 4.85 | 3.63 | 5.08 | 2.38 | 1.94 |
| Net working capital | 8.40 | (21.42) | 16.84 | 17.56 | 22.96 | 13.61 | 10.50 |
| Cash flow | |||||||
| Cash from operations | 3.02 | 14.15 | 7.78 | 7.98 | 13.07 | 10.20 | 2.88 |
| Cash from investing | (0.01) | 2.69 | (9.38) | (10.51) | (10.98) | (11.93) | (3.39) |
| Cash from financing | (3.52) | (17.71) | 2.66 | 0.85 | 0.55 | 2.15 | (1.99) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.40 | 18.13 | 18.85 | 15.56 | 17.26 | 16.06 | 20.73 | 16.22 |
| Revenue growth (YoY) | +29.8% | +12.9% | -9.1% | -4.1% | -25.0% | -32.6% | - | - |
| Other income | 1.20 | 6.84 | 2.31 | 3.55 | 2.49 | 4.32 | 3.94 | 1.93 |
| EBITDA | 4.17 | 2.87 | (2.75) | 0.18 | 0.96 | 0.89 | 0.99 | 0.67 |
| EBITDA margin | +18.6% | +15.8% | -14.6% | +1.2% | +5.6% | +5.5% | +4.8% | +4.1% |
| Depreciation | 0.65 | 0.67 | 0.76 | 0.71 | 0.69 | 0.66 | 0.76 | 0.80 |
| Interest | 0.14 | 0.16 | 0.15 | 0.20 | 0.18 | 0.18 | 0.21 | 0.19 |
| Profit before tax | 4.58 | 8.88 | (1.35) | 2.82 | 2.58 | 4.37 | 3.96 | 1.61 |
| Tax | 1.63 | 1.41 | (0.79) | 0.52 | 0.65 | 0.65 | 1.21 | 0.94 |
| Net profit | 2.95 | 7.47 | (0.56) | 2.30 | 1.93 | 3.72 | 2.75 | 0.67 |
| EPS (βΉ) | 5.27 | 13.34 | 2.61 | 3.51 | 5.78 | 6.75 | 3.70 | 1.18 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 67.33 | 66.30 | 66.88 | 59.71 | 55.11 | 49.12 | 46.81 |
| Revenue growth | +1.6% | -0.9% | +12.0% | +8.4% | +12.2% | +4.9% | - |
| EBITDA | 2.18 | 5.26 | 4.64 | 6.98 | 8.67 | 9.59 | (0.66) |
| EBITDA margin | +3.2% | +7.9% | +6.9% | +11.7% | +15.7% | +19.5% | -1.4% |
| Profit before tax | 9.74 | 14.37 | 61.52 | 28.10 | 30.43 | 9.80 | 1.12 |
| Net profit | 8.94 | 6.42 | 14.15 | 7.31 | 7.93 | 7.53 | (2.43) |
| Net profit margin | +13.3% | +9.7% | +21.2% | +12.2% | +14.4% | +15.3% | -5.2% |
| EPS (βΉ) | 15.56 | 18.76 | 85.53 | 40.97 | 47.33 | 15.73 | 3.27 |
| Balance sheet | |||||||
| Total assets | 205 | 202 | 212 | 162 | 143 | 117 | 105 |
| Net worth | 197 | 190 | 197 | 155 | 137 | 113 | 101 |
| Total debt | 2.38 | 4.77 | 5.36 | (1.01) | (0.83) | (0.61) | (0.34) |
| Cash & bank | 2.33 | 1.55 | 1.33 | 2.91 | 4.71 | 2.00 | 1.54 |
| Net working capital | 7.12 | 5.51 | 7.48 | 5.28 | 14.22 | 8.32 | 8.24 |
| Cash flow | |||||||
| Cash from operations | 3.15 | 1.97 | (9.14) | 22.25 | 26.25 | 9.17 | 2.15 |
| Cash from investing | 1.83 | 16.08 | 6.87 | (19.48) | (22.26) | (11.68) | (2.21) |
| Cash from financing | (4.23) | (18.16) | 0.61 | (4.60) | (1.34) | 2.95 | (2.69) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.40 | 18.06 | 18.85 | 15.44 | 17.18 | 15.87 | 20.66 | 16.15 |
| Revenue growth (YoY) | +30.4% | +13.8% | -8.8% | -4.4% | +16.8% | +7.4% | - | - |
| Other income | 0.90 | 6.46 | 2.03 | 3.15 | 2.06 | 4.04 | 3.47 | 1.86 |
| Total expenses | 18.17 | 15.04 | 19.64 | 15.22 | 16.05 | 14.43 | 17.84 | 16.90 |
| EBITDA | 4.23 | 3.02 | (0.79) | 0.22 | 1.13 | 1.44 | 2.82 | (0.75) |
| EBITDA margin | +18.9% | +16.7% | -4.2% | +1.4% | +6.6% | +9.1% | +13.6% | -4.6% |
| Depreciation | 0.65 | 0.67 | 0.76 | 0.71 | 0.69 | 0.66 | 0.76 | 0.80 |
| Interest | 0.14 | 0.16 | 0.15 | 0.20 | 0.18 | 0.18 | 0.21 | 0.19 |
| Profit before tax | 4.34 | 8.65 | 0.33 | 2.46 | 2.32 | 4.64 | 5.32 | 0.12 |
| Tax | 1.63 | 1.41 | (0.79) | 0.52 | 0.65 | 0.65 | 1.21 | 0.94 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.40 | 18.13 | 18.85 | 15.56 | 17.26 | 16.06 | 20.73 | 16.22 |
| Revenue growth (YoY) | +29.8% | +12.9% | -9.1% | -4.1% | -25.0% | -32.6% | - | - |
| Other income | 1.20 | 6.84 | 2.31 | 3.55 | 2.49 | 4.32 | 3.94 | 1.93 |
| EBITDA | 4.17 | 2.87 | (2.75) | 0.18 | 0.96 | 0.89 | 0.99 | 0.67 |
| EBITDA margin | +18.6% | +15.8% | -14.6% | +1.2% | +5.6% | +5.5% | +4.8% | +4.1% |
| Depreciation | 0.65 | 0.67 | 0.76 | 0.71 | 0.69 | 0.66 | 0.76 | 0.80 |
| Interest | 0.14 | 0.16 | 0.15 | 0.20 | 0.18 | 0.18 | 0.21 | 0.19 |
| Profit before tax | 4.58 | 8.88 | (1.35) | 2.82 | 2.58 | 4.37 | 3.96 | 1.61 |
| Tax | 1.63 | 1.41 | (0.79) | 0.52 | 0.65 | 0.65 | 1.21 | 0.94 |
| Net profit | 2.95 | 7.47 | (0.56) | 2.30 | 1.93 | 3.72 | 2.75 | 0.67 |
| EPS (βΉ) | 5.27 | 13.34 | 2.61 | 3.51 | 5.78 | 6.75 | 3.70 | 1.18 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 67.72 | 66.53 | 67.12 | 98.17 | 90.16 | 74.16 | 66.16 |
| Revenue growth | +1.8% | -0.9% | -31.6% | +8.9% | +21.6% | +12.1% | - |
| Other income | 12.23 | 13.85 | 60.63 | 25.39 | 25.58 | 4.80 | 7.60 |
| Total expenses | 67.98 | 64.74 | 64.54 | 87.21 | 73.33 | 60.57 | 65.75 |
| Employee cost | 24.51 | 23.28 | 22.24 | 22.98 | 21.37 | 19.23 | 19.81 |
| EBITDA | (0.26) | 1.79 | 2.58 | 10.96 | 16.83 | 13.59 | 0.41 |
| EBITDA margin | -0.4% | +2.7% | +3.8% | +11.2% | +18.7% | +18.3% | +0.6% |
| Depreciation | 2.83 | 3.02 | 2.81 | 5.77 | 5.17 | 5.89 | 7.05 |
| Interest | 0.71 | 0.77 | 0.16 | 1.51 | 0.65 | 0.82 | 0.82 |
| Profit before tax | 8.43 | 11.85 | 60.24 | 29.07 | 36.59 | 11.68 | 0.14 |
| Tax | 1.02 | 3.87 | 13.61 | 5.17 | 3.93 | 1.00 | (0.61) |
| Net profit | 9.41 | 6.85 | 11.94 | 7.97 | 10.97 | 8.50 | (3.08) |
| Net profit margin | +13.9% | +10.3% | +17.8% | +8.1% | +12.2% | +11.5% | -4.7% |
| EPS (βΉ) | 13.57 | 18.73 | 90.25 | 42.38 | 53.61 | 17.53 | 2.07 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 5.60 | 5.66 | 6.02 | 6.01 | 5.99 | 5.60 | 5.30 |
| Reserves & surplus | 195 | 189 | 196 | 151 | 132 | 105 | 90.77 |
| Shareholders' funds (net worth) | 200 | 194 | 202 | 157 | 138 | 111 | 97.20 |
| Minority interest | 0.00 | 4.98 | 7.49 | 11.42 | 11.25 | 8.59 | 7.74 |
| Secured loans | 2.38 | 4.77 | 23.80 | 13.63 | 7.09 | 5.34 | 5.39 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 |
| Total debt | 2.38 | 4.77 | 23.80 | 13.63 | 7.09 | 5.34 | 5.55 |
| Total liabilities | 208 | 211 | 243 | 193 | 163 | 129 | 115 |
| Assets | |||||||
| Gross block | 135 | 141 | 194 | 185 | 177 | 171 | 178 |
| Net block | 22.12 | 24.13 | 54.56 | 48.96 | 43.74 | 39.19 | 45.19 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 171 | 158 | 163 | 116 | 92.24 | 73.84 | 58.05 |
| Inventories | 14.71 | 15.80 | 19.44 | 15.87 | 18.87 | 16.27 | 14.58 |
| Sundry debtors | 4.97 | 5.34 | 15.14 | 14.86 | 13.82 | 10.67 | 11.76 |
| Cash & bank balances | 3.53 | 4.14 | 4.85 | 3.63 | 5.08 | 2.38 | 1.94 |
| Loans & advances | 5.95 | 6.38 | 5.34 | 9.41 | 8.56 | 1.74 | 2.62 |
| Total current assets | 29.16 | 31.66 | 44.77 | 43.77 | 46.33 | 31.06 | 30.90 |
| Total current liabilities | 20.76 | 53.08 | 27.93 | 26.21 | 23.37 | 17.45 | 20.40 |
| Net working capital | 8.40 | (21.42) | 16.84 | 17.56 | 22.96 | 13.61 | 10.50 |
| Total assets | 208 | 211 | 243 | 193 | 163 | 129 | 115 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 3.31 | 4.19 | 3.14 | 4.81 | 2.17 | 1.75 | 4.25 |
| Net cash from operating activities | 3.02 | 14.15 | 7.78 | 7.98 | 13.07 | 10.20 | 2.88 |
| Net cash from investing activities | (0.01) | 2.69 | (9.38) | (10.51) | (10.98) | (11.93) | (3.39) |
| Net cash from financing activities | (3.52) | (17.71) | 2.66 | 0.85 | 0.55 | 2.15 | (1.99) |
| Net change in cash | (0.51) | (0.88) | 1.05 | (1.68) | 2.64 | 0.42 | (2.50) |
| Closing cash | 3.53 | 4.14 | 4.85 | 3.63 | 5.08 | 2.38 | 1.94 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +1.8% | -0.9% | -31.6% | +8.9% | +21.6% | +12.1% | - |
| EBITDA growth | -114.5% | -30.6% | -76.5% | -34.9% | +23.8% | +3214.6% | - |
| PBT growth | -28.9% | -80.3% | +107.2% | -20.6% | +213.3% | +8242.9% | +9998.0% |
| Net income growth | +37.4% | -42.6% | +49.8% | -27.4% | +29.1% | +376.0% | - |
| Revenue CAGR (3Y) | -11.6% | -9.6% | -3.3% | +14.1% | +0.3% | -7.1% | -11.8% |
| EBITDA CAGR (3Y) | - | -52.6% | -42.5% | +199.0% | +55.9% | - | -64.4% |
| Profitability & leverage | |||||||
| Net income margin | +10.9% | +12.0% | +69.5% | +24.4% | +36.2% | +14.4% | +1.1% |
| Return on capital employed | +5.7% | +5.7% | +9.3% | +6.4% | +11.4% | +9.5% | +0.2% |
| Return on net worth | +4.7% | +4.0% | +4.5% | +5.5% | +11.0% | +9.0% | -3.5% |
| Debt / equity | 0.02 | 0.07 | 0.10 | 0.07 | 0.05 | 0.05 | 0.07 |
| Long-term debt / equity | 0.03 | 0.05 | 0.08 | 0.06 | 0.03 | 0.01 | 0.02 |
| Interest cover | -22.98 | -62.60 | -69.57 | 29.09 | 5.57 | 10.65 | -12.35 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.49 | 0.40 | 0.35 | 0.54 | 0.52 | 0.43 | 0.32 |
| Inventory turnover | 4.44 | 3.78 | 3.80 | 5.65 | 5.13 | 4.81 | 3.54 |
| Debtors turnover | 13.14 | 6.50 | 4.47 | 6.85 | 7.36 | 6.61 | 5.32 |
| EPS (βΉ) | 13.57 | 18.73 | 90.25 | 42.38 | 53.61 | 17.53 | 2.07 |
| Dividend per share (βΉ) | 1.50 | 2.00 | 30.00 | 10.00 | 7.50 | 5.00 | 3.00 |
| Book value per share (βΉ) | 357.62 | 346.91 | 359.72 | 280.33 | 245.76 | 197.41 | 181.24 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.40 | 18.06 | 18.85 | 15.44 | 17.18 | 15.87 | 20.66 | 16.15 |
| Revenue growth (YoY) | +30.4% | +13.8% | -8.8% | -4.4% | +16.8% | +7.4% | - | - |
| Other income | 0.90 | 6.46 | 2.03 | 3.15 | 2.06 | 4.04 | 3.47 | 1.86 |
| Total expenses | 18.17 | 15.04 | 19.64 | 15.22 | 16.05 | 14.43 | 17.84 | 16.90 |
| EBITDA | 4.23 | 3.02 | (0.79) | 0.22 | 1.13 | 1.44 | 2.82 | (0.75) |
| EBITDA margin | +18.9% | +16.7% | -4.2% | +1.4% | +6.6% | +9.1% | +13.6% | -4.6% |
| Depreciation | 0.65 | 0.67 | 0.76 | 0.71 | 0.69 | 0.66 | 0.76 | 0.80 |
| Interest | 0.14 | 0.16 | 0.15 | 0.20 | 0.18 | 0.18 | 0.21 | 0.19 |
| Profit before tax | 4.34 | 8.65 | 0.33 | 2.46 | 2.32 | 4.64 | 5.32 | 0.12 |
| Tax | 1.63 | 1.41 | (0.79) | 0.52 | 0.65 | 0.65 | 1.21 | 0.94 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 67.33 | 66.30 | 66.88 | 59.71 | 55.11 | 49.12 | 46.81 |
| Revenue growth | +1.6% | -0.9% | +12.0% | +8.4% | +12.2% | +4.9% | - |
| Other income | 11.10 | 12.90 | 59.85 | 24.72 | 25.30 | 4.64 | 7.42 |
| Total expenses | 65.15 | 61.04 | 62.24 | 52.73 | 46.44 | 39.53 | 47.47 |
| Employee cost | 24.51 | 23.28 | 22.24 | 18.26 | 16.64 | 15.83 | 16.54 |
| EBITDA | 2.18 | 5.26 | 4.64 | 6.98 | 8.67 | 9.59 | (0.66) |
| EBITDA margin | +3.2% | +7.9% | +6.9% | +11.7% | +15.7% | +19.5% | -1.4% |
| Depreciation | 2.83 | 3.02 | 2.81 | 3.45 | 3.41 | 4.23 | 5.43 |
| Interest | 0.71 | 0.77 | 0.16 | 0.15 | 0.13 | 0.20 | 0.21 |
| Profit before tax | 9.74 | 14.37 | 61.52 | 28.10 | 30.43 | 9.80 | 1.12 |
| Tax | 1.02 | 3.87 | 13.61 | 5.17 | 3.93 | 1.00 | (0.61) |
| Net profit | 8.94 | 6.42 | 14.15 | 7.31 | 7.93 | 7.53 | (2.43) |
| Net profit margin | +13.3% | +9.7% | +21.2% | +12.2% | +14.4% | +15.3% | -5.2% |
| EPS (βΉ) | 15.56 | 18.76 | 85.53 | 40.97 | 47.33 | 15.73 | 3.27 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 5.60 | 5.60 | 5.60 | 5.60 | 5.60 | 5.60 | 5.30 |
| Reserves & surplus | 192 | 184 | 191 | 150 | 131 | 108 | 94.42 |
| Shareholders' funds (net worth) | 197 | 190 | 197 | 155 | 137 | 113 | 101 |
| Secured loans | 2.38 | 4.77 | 5.36 | (1.01) | (0.83) | (0.61) | (0.34) |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 2.38 | 4.77 | 5.36 | (1.01) | (0.83) | (0.61) | (0.34) |
| Total liabilities | 205 | 202 | 212 | 162 | 143 | 117 | 105 |
| Assets | |||||||
| Gross block | 135 | 141 | 137 | 128 | 130 | 132 | 140 |
| Net block | 22.12 | 24.13 | 22.88 | 15.75 | 17.03 | 19.44 | 24.41 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 169 | 158 | 174 | 131 | 108 | 87.39 | 71.25 |
| Inventories | 14.71 | 15.80 | 15.40 | 11.97 | 13.36 | 12.91 | 12.39 |
| Sundry debtors | 4.92 | 5.27 | 5.22 | 5.28 | 4.94 | 5.19 | 7.16 |
| Cash & bank balances | 2.33 | 1.55 | 1.33 | 2.91 | 4.71 | 2.00 | 1.54 |
| Loans & advances | 5.91 | 6.30 | 4.74 | 5.90 | 7.27 | 1.44 | 2.49 |
| Total current assets | 27.87 | 28.92 | 26.69 | 26.06 | 30.28 | 21.54 | 23.58 |
| Total current liabilities | 20.75 | 23.41 | 19.21 | 20.78 | 16.06 | 13.22 | 15.34 |
| Net working capital | 7.12 | 5.51 | 7.48 | 5.28 | 14.22 | 8.32 | 8.24 |
| Total assets | 205 | 202 | 212 | 162 | 143 | 117 | 105 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.86 | 0.97 | 2.63 | 4.45 | 1.79 | 1.35 | 4.10 |
| Net cash from operating activities | 3.15 | 1.97 | (9.14) | 22.25 | 26.25 | 9.17 | 2.15 |
| Net cash from investing activities | 1.83 | 16.08 | 6.87 | (19.48) | (22.26) | (11.68) | (2.21) |
| Net cash from financing activities | (4.23) | (18.16) | 0.61 | (4.60) | (1.34) | 2.95 | (2.69) |
| Net change in cash | 0.75 | (0.11) | (1.66) | (1.82) | 2.65 | 0.45 | (2.76) |
| Closing cash | 2.33 | 1.55 | 1.33 | 2.91 | 4.71 | 2.00 | 1.54 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +1.6% | -0.9% | +12.0% | +8.4% | +12.2% | +4.9% | - |
| EBITDA growth | -58.6% | +13.4% | -33.5% | -19.5% | -9.6% | +1553.0% | - |
| PBT growth | -32.2% | -76.6% | +118.9% | -7.7% | +210.5% | +775.0% | +9998.0% |
| Net income growth | +39.3% | -54.6% | +93.6% | -7.8% | +5.3% | +409.9% | - |
| Revenue CAGR (3Y) | +4.1% | +6.4% | +10.8% | +8.5% | -7.1% | -13.9% | -16.1% |
| EBITDA CAGR (3Y) | -32.2% | -15.3% | -21.5% | - | +42.8% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +13.0% | +15.8% | +71.6% | +38.4% | +48.1% | +17.9% | +3.7% |
| Return on capital employed | +5.1% | +5.8% | +9.8% | +5.5% | +6.8% | +7.6% | -2.7% |
| Return on net worth | +4.5% | +3.3% | +8.0% | +5.0% | +6.4% | +7.1% | -2.4% |
| Debt / equity | 0.02 | 0.03 | 0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| Long-term debt / equity | 0.03 | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | -109.23 | 34.38 | 8.74 | 4.25 | 2.47 | 3.73 | -3.45 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.49 | 0.48 | 0.50 | 0.46 | 0.42 | 0.36 | 0.27 |
| Inventory turnover | 4.41 | 4.25 | 4.89 | 4.71 | 4.20 | 3.88 | 2.90 |
| Debtors turnover | 13.21 | 12.64 | 12.74 | 11.68 | 10.88 | 7.95 | 6.64 |
| EPS (βΉ) | 15.56 | 18.76 | 85.53 | 40.97 | 47.33 | 15.73 | 3.27 |
| Dividend per share (βΉ) | 1.50 | 2.00 | 30.00 | 10.00 | 7.50 | 5.00 | 3.00 |
| Book value per share (βΉ) | 352.14 | 339.08 | 351.74 | 277.37 | 244.26 | 202.13 | 188.13 |
Similar companies to Dinesh Mills
Dinesh Mills has 3 listed similar companies in our database, 2 of them funded. They include Akums, Jubilant Life Sciences and Nectar Lifesciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| akums.in | 2004 | Delhi, India | $70M | 395 | CDMO focusing on spectrum of dosage forms and therapeutic segments | |
| jubl.com | 1978 | Noida, India | Company offering a suite of R&D and manufacturing services for small molecules and generics | |||
| neclife.com | 1995 | Chandigarh, India | $46.85M | 175 | Cephalosporin APIs and generic formulations are manufactured. |
Detailed similar companies of Dinesh Mills
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Dinesh Mills
Websites that share an audience with Dinesh Mills (dineshmills.com).
Websites whose visitors overlap most with Dinesh Mills. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| zjhuading.com | 100% | View details | |||
bruch.be | bruch.be | 100% | β | ||
| ik-felt.co.jp | 100% | 5.4K | #3,188,476 | View details | |
wrt-belt.com | wrt-belt.com | 100% | β | ||
polyestermesh.net | polyestermesh.net | 100% | β | ||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 15 similar websites and full traffic analytics for Dinesh Mills
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Dinesh Mills (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dinesh Mills
Complete news archive for Dinesh Mills
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dinesh Mills
Dinesh Mills was founded in 1935.
Dinesh Mills is headquartered in Vadodara, India. It is registered at Vadodara, Gujarat, India.
Dinesh Mills has 322 employees.
The primary company behind Dinesh Mills, Shri Dinesh Mills Limited, reported revenue of βΉ79.95 Cr for FY 2026, up 2% year on year.
Dinesh Mills was established in 1935 in Vadodara, India, where operations center on the production of machinery for capsule manufacturing. The company serves the pharmaceutical equipment sector by providing machines used in capsule filling and production processes. Leadership is provided by Managing Director and Chairman Bharat Patel, with activities based primarily in the Indian market. Focus remains on industrial manufacturing standards and local operations.
Dinesh Mills's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Yes, Dinesh Mills is publicly traded on BSE under the ticker symbol SHRIDINE.
Dinesh Mills operates through Shri Dinesh Mills Limited.
The legal entities of Dinesh Mills currently have 10 directors, including Bharat Upendra Patel, Reshma Suresh Patel, Mohan Vyankatesh Akalkotkar and others.
